15th Jun 2020 15:44
NetScientific PLC - Ashford-based healthcare IP commercialisation firm - Says portfolio firm PDS Biotechnology Corp begins Phase 2 clinical study of PDS0101 cancer medication. Net Scientific owns 7.2% stake in PDS.
Current stock price: 6.40 pence
Year-to-date change: down 5.2%
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Netscientific